Previous Close | 67.08 |
Open | 67.45 |
Bid | 65.26 x 400 |
Ask | 65.33 x 200 |
Day's Range | 65.09 - 67.90 |
52 Week Range | 65.09 - 87.87 |
Volume | |
Avg. Volume | 7,349,480 |
Market Cap | 81.39B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 14.50 |
EPS (TTM) | 4.50 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 3.08 (4.72%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 78.36 |
Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.